Exploring the Therapeutic Effect of Lumannate Sodium Capsules Combined with Donepezil Hydrochloride Tablets in the Treatment of Mild to Moderate Alzheimer's Disease Based on Neurotransmitters and Gut Microbiota
Objective:To investigate the changes in neurotransmitters,cognitive function,and gut microbiota in patients with mild to moderate Alzheimer's disease(AD)treated with a combination of donepezil hydrochloride tablets and mannitol sodium capsules.Methods:The random number table method was used,102 AD patients admitted to our hospital from March 2020 to March 2023 were divided into control group(n=51,treated with donepezil hydrochloride tablets)and study group(n=51,treated with ganlute sodium capsules combine with donepezil hydrochloride tablets).The related scale scores,neurotransmitters and intestinal flora in two groups were compared.Results:The score of Mini-Mental State Examination(MMSE),Activity of Daily Living(ADL),serum acetylcholine(Ach),5-hydroxytryptamine(5-HT)and glutamic acid(Glu),number of fecal Bifidobacterium and Lactobacillus in study group was higher than that in control group 6 months after treatment,and the scores of Behavioral Pathology of Dementia(BEHAVE-AD),number offecal Clostridium,Staphylococcus,Pseudomonas and Bacillus proteus in study group were lower than those in control group(P＜0.05).Conclusion:Combination treatment of donepezil hydrochloride tablets and mannitol sodium capsules for mild to moderate AD patients,can improve cognitive function,regulate neurotransmitters and gut microbiota.
Ganlute sodium capsulesMild to moderateAlzheimer's diseaseDonepezil hydrochloride tabletsCognitive functionIntestinal microbiotaNeurotransmitters
NETL
NSTL
万方数据
